异动解读 | 再鼎医药盘中大跌5.48%,分析师下调评级目标价或是主因

异动解读
03 Mar

再鼎医药(ZLAB)今日盘中大跌5.48%,引发市场广泛关注。公司在业务方面获得新利好,即其一款药品repotrectinib在台湾地区获批上市。但分析师下调对公司的评级和目标价或是导致股价下跌的主因。

具体来说,美银美林证券下调了再鼎医药的评级,由之前的"买入"调整为"中性",同时下调了公司目标价格,由之前的29美元调整至36.10美元。这引发了市场对公司发展前景的担忧,令股价承压。

对于分析师下调评级和目标价的具体原因,目前公司尚未作出回应。投资者期待公司能尽快解释清楚,并重申公司的发展方向和目标,以重拾市场信心。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10